Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 21 February 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Predicting safety and success of reinitiation of infliximab therapy

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy, reports the latest issue of the Clinical Gastroenterology & Hepatology.

News image

fiogf49gjkf04

Few agents are available for the treatment of inflammatory bowel diseases, and patients frequently become unresponsive to biologics.

Dr Filip Baert and colleagues from Belgium investigated the feasibility of reinitiating infliximab therapy for patients who previously received only episodic therapy with, lost response to, or had infusion reactions to infliximab.

The researchers identified factors associated with the success and safety of restarting infliximab, such as antibodies to infliximab and trough levels of the drug.

From the inflammatory bowel disease biobank, the team identified 128 consecutive patients who restarted infliximab after a median 15-month discontinuation.

The researchers also analyzed serum samples that had been collected during the first period of infliximab therapy, when therapy was reinitiated, and at later time points for trough levels and antibodies to infliximab.

15 patients had acute infusion reactions
Clinical Gastroenterology & Hepatology

The team investigated correlations among response to treatment, infusion reactions, treatment modalities, trough levels, and antibodies to infliximab.

Reinitiation of infliximab therapy produced a response in 84.5% of patients at week 14, 70% of patients at 1 year, and in 61% of patients at more than 4 years.

The research team found that 15 patients had acute infusion reactions, and 10 patients had delayed infusion reactions.

The absence of antibodies to infliximab at T+1 and reinitiation with concomitant immunomodulator therapy were associated with short-term responses.

The team noted that pregnancy or remission as reason for discontinuation, and higher trough levels at T+1 were associated with long-term response.

Undetectable antibodies to infliximab at T+1 were associated with the safety of reinitiating therapy HR for infusion reaction with detectable antibodies to infliximab.

Dr Baert's team concludes, "Reinitiating infliximab therapy can be safe and effective for patients with Crohn's disease or ulcerative colitis after a median 15-month discontinuation period."

Clin Gastroenterol Hepatol 2014: 12(9): 14741481.e2
03 September 2014

Go to top of page Email this page Email this page to a colleague

 21 February 2017 
Cancer survival in Lynch syndrome 
 21 February 2017 
Motor peripheral nerve injury after colorectal surgery
 21 February 2017 
Anesthetics during outpatient gastroenterology procedures
 20 February 2017 
Advanced neoplasms with low-risk adenomas
 20 February 2017 
Concepts of cirrhotic coagulopathy
 20 February 2017 
Smoking at diagnosis and colon cancer survival
 17 February 2017 
Genetic mutations predict esophageal cancer
 17 February 2017 
Genetic mutations predict esophageal cancer
 17 February 2017 
Anesthesia services during outpatient gastroenterology procedures
 16 February 2017 
Hysterectomy and pelvic floor disorders
 16 February 2017 
Anesthetist-directed sedation in endoscopic procedures
 16 February 2017 
Assisted reproduction in women with IBD 
 15 February 2017 
Metal stents for palliation in malignant biliary obstruction
 15 February 2017 
Hepatocellular carcinoma in the USA
 15 February 2017 
Increasing screening of cirrhosis in hepatocellular carcinoma
 14 February 2017 
Pathologists agreement in the diagnosis of Barrett's
 14 February 2017 
Preventive care in IBD 
 14 February 2017 
Infliximab dose for acute severe ulcerative colitis
 13 February 2017 
Vasoactive drugs for hepatorenal syndrome type 1
 13 February 2017 
Pregnancy outcomes after endoscopy
 13 February 2017 
H. pylori treatment guidelines
 10 February 2017 
Primary ileocecal resection in pediatric Crohn's disease
 10 February 2017 
Non-adherence in end-stage liver disease
 10 February 2017 
Isolated colonic Crohn's disease
 09 February 2017 
Mucosal healing in ulcerative colitis
 09 February 2017 
NAFLD and coronary artery calcium score
 09 February 2017 
Prevalence of Hep D in chronic Hep B infection
 08 February 2017 
Rifaximin for small intestine bacterial overgrowth
 08 February 2017 
Risk prediction of interval cancers from inadequate colonoscopy quality
 08 February 2017 
Meta-analyses in gastroenterology and hepatology journals
 07 February 2017 
Chemoprevention in colon cancer
 07 February 2017 
Methotrexate intolerance in pediatric IBD 
 07 February 2017 
Untreated hepatocellular carcinoma in the USA
 06 February 2017 
Vitamin D levels and risk of relapse in ulcerative colitis
 06 February 2017 
Giardia in the USA
 06 February 2017 
Colorectal cancer risk in serrated polyposis syndrome
 03 February 2017 
Helicobacter and Campylobacter in IBD
 03 February 2017 
Mortality risk in elderly-onset IBD
 03 February 2017 
Management of chronic refractory pouchitis
 02 February 2017 
IBD-related research and publications
 02 February 2017 
TWEAK in IBD
 02 February 2017 
Clostridium difficile and colectomy risk in IBD
 01 February 2017 
Suboptimal bowel preparation in outpatient colonoscopy
 01 February 2017 
Fecal microbiota transplantation
 01 February 2017 
Socio-economic distribution of IBD 
 31 January 2017 
Gastroenterology fellowship
 31 January 2017 
Approach to Lynch syndrome
 31 January 2017 
Fat intake and ulcerative colitis risk
 30 January 2017 
Dietary risk of acute pancreatitis
 30 January 2017 
Care pathway for anemia in IBD 
 30 January 2017 
Mortality in elderly-onset IBD
 27 January 2017 
Therapeutic drug monitoring in IBD 
 27 January 2017 
Cancer mortality in the USA
 27 January 2017 
Monoclonal antibodies for recurrent C. diff
 26 January 2017 
Propofol for gastrointestinal endoscopy
 26 January 2017 
Therapy in pediatric IBD
 26 January 2017 
Disease knowledge in adolescents with IBD
 24 January 2017 
Course of achalasia
 24 January 2017 
H. pylori and iron deficiency anemia
 24 January 2017 
Hospital transfer and colorectal surgery

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us